Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Erasca, Inc.

Get SEC filing alerts via email and in your feed for Erasca, Inc.

ERAS

Erasca, Inc.

About Erasca, Inc.

Erasca is a clinical-stage precision oncology company focused on developing therapies targeting the RAS/MAPK pathway, a key driver in many cancers. Its pipeline includes small and large molecule therapeutics, such as pan-RAF, RAS, and EGFR inhibitors, aimed at treating high unmet medical needs across diverse tumor types. The company emphasizes combination regimens to shut down cancer signaling pathways and improve patient outcomes.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Erasca, Inc.

1
1
Erasca, Inc. Erasca Reports $183.4 Million Net Loss and Significant R&D Investment in Latest 10-Q

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Erasca, Inc. Erasca Reports $124.5 Million Net Loss for 2025, Decreases R&D Expenses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Erasca, Inc. Erasca Reports Q3 2025 Financial Results with $30.6 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Erasca, Inc. Erasca Reports $33.9 Million Net Loss in Q2 2025, Down from $63.2 Million Last Year

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Erasca, Inc. Erasca Reports $30.97 Million Net Loss in Q1 2025, Decreased from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Erasca, Inc. Erasca Reports $161.65 Million Net Loss for 2024, Driven by Increased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Erasca, Inc. Erasca, Inc. Reports Financial Developments, Increases Assets and Stockholders' Equity, and Reduces Workforce

Via official filing (AI summary) | over 1 year ago | 0 comments